|
Social determinants of substance use disorder treatment outcomes in a vulnerable population |
1R21DA055229-01 |
|
NIDA |
2022 |
|
A telehealth tDCS approach to decrease cannabis use: Towards reducing multiple sclerosis disability in multiple sclerosis |
1R21DA055427-01 |
|
NIDA |
2022 |
|
Psychostimulants, Attention Deficit and Basal Ganglia Disorders |
1R21DA055980-01 |
|
NIDA |
2022 |
|
Dissecting functional roles of MeCP2 condensates in neurons with chemogenetic tools |
1R21DA056293-01 |
|
NIDA |
2022 |
|
A pilot study of ambulatory Heart Rate Variability Biofeedback for substance use disorder |
1R21DA056468-01 |
|
NIDA |
2022 |
|
Deep Brain Stimulation (DBS) For Severe Treatment Refractory Methamphetamine Use Disorder |
1UG3DA054746-01A1 |
|
NIDA |
2022 |
|
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse |
2R01DA041931-07A1 |
|
NIDA |
2022 |
|
Wearable sensor for opioids detection based on electrochemical sensor arrayintegrated with Bluetooth device |
2R44DA051289-02 |
|
NIDA |
2022 |
|
Neural circuitry mediating behavioral flexibility |
3R00DA042934-05S2 |
|
NIDA |
2022 |
|
Leveraging ΔFosB as a potential therapeutic for Alzheimers Disease |
3R01DA040621-07S1 |
|
NIDA |
2022 |